Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial

M.A. Elliott; E. Prasad; S.J. Ford; G.W. Halbert

Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial

M.A. Elliott, E. Prasad, S.J. Ford, G.W. Halbert

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to conference › Poster › peer-review

4 Downloads (Pure)

Abstract

Fenretinide is a pro-apoptotic, cytotoxic, synthetic Vitamin A analogue with application in the treatment of Ewing’s sarcoma. For pediatric study, a ‘cookie dough’ formulation had been developed, improving upon an existing corn oil formulation. We report on a simplified capsular formulation of Fenretinide with the novel solubility and bioavailability enhancing lipid matrix, Lym-X-Sorb™.

Original language	English
Pages	1433-1434
Publication status	Published - 3 Sept 2010
Event	UK-PharmSci 2010 – The Science of Medicines - Nottingham, United Kingdom Duration: 1 Sept 2010 → 3 Sept 2010

Conference

Conference	UK-PharmSci 2010 – The Science of Medicines
Country/Territory	United Kingdom
City	Nottingham
Period	1/09/10 → 3/09/10

Access to Document

Elliot-etal-PharmSci-2010-Experiences-of-melt-fi-ll-production-of-Fenretinide-Lym-X-Sorb-hard-gelatin-capsulesOther version, 213 KB

Cancer Research UK Formulation Unit 2007/2008
Halbert, G.
Cancer Research UK CRUK
1/10/07 → 31/03/10
Project: Research

Cite this

@conference{246b7754f0a541668f1ac05b9431f7f2,

title = "Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb{\texttrademark} hard gelatin capsules for Phase I clinical trial",

abstract = "Fenretinide is a pro-apoptotic, cytotoxic, synthetic Vitamin A analogue with application in the treatment of Ewing{\textquoteright}s sarcoma. For pediatric study, a {\textquoteleft}cookie dough{\textquoteright} formulation had been developed, improving upon an existing corn oil formulation. We report on a simplified capsular formulation of Fenretinide with the novel solubility and bioavailability enhancing lipid matrix, Lym-X-Sorb{\texttrademark}.",

author = "M.A. Elliott and E. Prasad and S.J. Ford and G.W. Halbert",

year = "2010",

month = sep,

day = "3",

language = "English",

pages = "1433--1434",

note = "UK-PharmSci 2010 – The Science of Medicines ; Conference date: 01-09-2010 Through 03-09-2010",

}

TY - CONF

T1 - Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial

AU - Elliott, M.A.

AU - Prasad, E.

AU - Ford, S.J.

AU - Halbert, G.W.

PY - 2010/9/3

Y1 - 2010/9/3

N2 - Fenretinide is a pro-apoptotic, cytotoxic, synthetic Vitamin A analogue with application in the treatment of Ewing’s sarcoma. For pediatric study, a ‘cookie dough’ formulation had been developed, improving upon an existing corn oil formulation. We report on a simplified capsular formulation of Fenretinide with the novel solubility and bioavailability enhancing lipid matrix, Lym-X-Sorb™.

AB - Fenretinide is a pro-apoptotic, cytotoxic, synthetic Vitamin A analogue with application in the treatment of Ewing’s sarcoma. For pediatric study, a ‘cookie dough’ formulation had been developed, improving upon an existing corn oil formulation. We report on a simplified capsular formulation of Fenretinide with the novel solubility and bioavailability enhancing lipid matrix, Lym-X-Sorb™.

M3 - Poster

SP - 1433

EP - 1434

T2 - UK-PharmSci 2010 – The Science of Medicines

Y2 - 1 September 2010 through 3 September 2010

ER -

Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial

Abstract

Conference

Access to Document

Fingerprint

Projects

Cancer Research UK Formulation Unit 2007/2008

Cite this